Replies to post #333668 on Innovation Pharmaceuticals Inc (IPIX)

[Empiricst1]

I wonder that too, and it remains the reason I only buy small amounts at the various lows. But I do buy.

[olden_grumpini]

A possibility as to why BP and others are cautious about B was laid out in the April 2015 presentation of Brilacidin in ABSSSI. Here's the link to the slide deck:

Slide deck

The summary of Adverse Events and Conclusions are towards the end of the deck. Focus on the fact the conclusions of efficacy are based on a single dose.

Single-dose brilacidin was safe and well tolerated in a phase 2b ABSSSI study

There is no mention of the multi-dose regimen. In the multi-dose regimen >92% of the treated population had TEAEs of which >26% experienced hypertension >160 mmHg.

Much has been made of the RBL testing. Is this testing being done to simulate using brilacidin as a single dose?

From the RBL paper:

Figure 2A. Brilacidin inhibits SARS-CoV-2 replication (Vero cells)
(A) Vero cells were pretreated for 2h with 2 or 10µM brilacidin, infected with SARS-CoV-2 non-directly at MOI 0.1 for 1h, and post-treated with media containing brilacidin as described in Materials and Methods.

Figure 2D, 2E. Brilacidin appears to disrupt the integrity of the SARS-CoV-2 virion
(D) Vero cells were pre-treated for 2h with 10µM brilacidin. SARS-CoV-2 was diluted to MOI 0.1 in culture media containing brilacidin and incubated for 1h.

Figure 3. Brilacidin exhibits potent inhibition of SARS-CoV-2 in a human cell line (Calu-3 cells)
(A) Calu-3 cells were pretreated for 2h with 10 or 20µM brilacidin and infected with SARS-CoV-2 at MOI 0.1 non-directly or (B) directly with brilacidin for 1h as described in Materials and Methods.

How does the RBL testing of 10µM compare to the ABSSSI study using 0.6 mg/kg D1; 0.3 mg/kg D2 & D3?

Can anyone answer this last question?